Document Detail

DRD4 exon III polymorphism and response to risperidone in Israeli adolescents with schizophrenia: a pilot pharmacogenetic study.
MedLine Citation:
PMID:  12729944     Owner:  NLM     Status:  MEDLINE    
This study examined the possible association between the polymorphism in the dopamine receptor DRD4 gene and response to risperidone among 24 Israeli Jewish adolescent inpatients with first-episode schizophrenia. Response was categorically determined by a change of >40% on the Brief Psychiatric Rating Scale (BPRS). No significant association was found between the DRD4 genotype and clinical response, although carriers of <7 repeat alleles demonstrated higher response rate (10/20 vs. 0/4, P=0.11). Studies in larger groups of adolescent schizophrenia patients are warranted to clarify the possible association between DRD4 exon III repeat alleles and the response to risperidone.
Gil Zalsman; Amos Frisch; Shaul Lev-Ran; Andrés Martin; Elena Michaelovsky; Daniela Bensason; Doron Gothelf; Eitan Nahshoni; Samuel Tyano; Abraham Weizman
Related Documents :
19748074 - The role of dna copy number variation in schizophrenia.
2577274 - Strategies for linkage studies in schizophrenia.
17033634 - Plexin b3 is genetically associated with verbal performance and white matter volume in ...
15936534 - The x-box binding protein 1 (xbp1) gene is not associated with methamphetamine dependence.
21986704 - Causes and consequences of obesity: the contribution of recent twin studies.
16995614 - Sperm parasitism in ants: selection for interspecific mating and hybridization.
Publication Detail:
Type:  Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology     Volume:  13     ISSN:  0924-977X     ISO Abbreviation:  Eur Neuropsychopharmacol     Publication Date:  2003 May 
Date Detail:
Created Date:  2003-05-05     Completed Date:  2003-07-11     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  9111390     Medline TA:  Eur Neuropsychopharmacol     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  183-5     Citation Subset:  IM    
Adolescent Inpatient Department, Geha Mental Health Center, Rabin Medical Center, Petach Tikva 49100, Israel.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antipsychotic Agents / therapeutic use*
DNA / genetics
Exons / genetics*
Gene Frequency
Pilot Projects
Polymorphism, Genetic / genetics*
Psychiatric Status Rating Scales
Receptors, Dopamine D2 / genetics*
Receptors, Dopamine D4
Risperidone / therapeutic use*
Schizophrenia / drug therapy*,  genetics*
Reg. No./Substance:
0/Antipsychotic Agents; 0/DRD4 protein, human; 0/Receptors, Dopamine D2; 106266-06-2/Risperidone; 137750-34-6/Receptors, Dopamine D4; 9007-49-2/DNA

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Anti-cataleptic effects of clozapine, but not olanzapine and quetiapine, on SCH 23390- or raclopride...
Next Document:  Neonatal lesions in the amygdala or ventral hippocampus disrupt prepulse inhibition of the acoustic ...